Sequencing in EGFR+ NSCLC: How MET Amplifications and Other Factors Guide Decisions

Samuel Rosner, MD, and Laura Alder, MD, discuss how resistance mechanisms shape treatment sequencing strategies in EGFR-mutated non–small cell lung cancer. Rosner reviews common drivers of disease progression, including MET amplification and other molecular alterations that may emerge following EGFR-targeted therapy. Alder explains how repeat molecular testing and evolving tumor biology can guide subsequent treatment decisions and help optimize therapeutic sequencing.